SCHEMBL12285232

SCHEMBL12285232

C=C(C)C(=O)OCOC12CC3CC(C1)OC(=O)C(C3)C2

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ALDH1A1 P00352 1/20 0.33
NAAA Q02083 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14648951 0.94 TSHR (0.33) TSHRNPSR1ALDH1A1
SCHEMBL13649558 0.91 NAAA (0.30) NAAA
SCHEMBL18351248 0.90 THRB (0.33) TSHRNPSR1ALDH1A1NAAA
SCHEMBL14648973 0.90 TSHR (0.30) TSHRNPSR1
SCHEMBL18351249 0.86 THRB (0.31) TSHRNPSR1
SCHEMBL14648994 0.86 TSHR (0.34) TSHRNPSR1
SCHEMBL14648959 0.85 TSHR (0.38) TSHRNPSR1NAAA
SCHEMBL17668300 0.84 NAAA (0.40) TSHRNPSR1NAAA
SCHEMBL14997755 0.84 NAAA (0.40) TSHRNPSR1NAAA
SCHEMBL74710 0.84 NAAA (0.40) TSHRNPSR1NAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10571805-B2 Resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2020-02-25 US disclosed
US-20160377978-A1 RESIST COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-12-29 US disclosed
US-20150316847-A1 HOMOADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME AND PHOTOSENSITIVE MATERIALS FOR PHOTORESIST OSAKA ORGANIC CHEMICAL INDUSTRY LTD. (JP) 2015-11-05 US disclosed
US-20150316847-A1 HOMOADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME AND PHOTOSENSITIVE MATERIALS FOR PHOTORESIST OSAKA ORGANIC CHEMICAL INDUSTRY LTD. (JP) 2015-11-05 US disclosed
US-20130022914-A1 HOMOADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME AND PHOTOSENSITIVE MATERIALS FOR PHOTORESIST IDEMITSU KOSAN CO., LTD. (JP) 2013-01-24 US disclosed
US-20130022914-A1 HOMOADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME AND PHOTOSENSITIVE MATERIALS FOR PHOTORESIST IDEMITSU KOSAN CO., LTD. (JP) 2013-01-24 US disclosed
WO-2011125291-A1 HOMOADAMANTANE DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHOTOSENSITIVE MATERIAL FOR PHOTORESIST 出光興産株式会社 (JP) 2011-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022914-A1 HOMOADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME AND PHOTOSENSITIVE MATERIALS FOR PHOTORESIST CRY1, HPD, CRY2 TSHR 1142/4885NPSR1 142/4885ALDH1A1 2462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.